Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -96.78% is 15% below its 5-year average of -84.15%, around the middle of its 5-year range (-243.81%–-31.93%).
187.78% below its 12-month average of -33.63%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -25.32%.
RETURN ON ASSETS (ROA)
-96.78%
RETURN ON ASSETS (ROA) AVG TTM
-33.63%
RETURN ON ASSETS (ROA) AVG 3Y
-87.61%
RETURN ON ASSETS (ROA) AVG 5Y
-84.15%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-187.78%
CURRENT VS 3Y AVG
-10.47%
CURRENT VS 5Y AVG
-15.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
-232.01%
vs the sector median at left
Korsana Biosciences, Inc.
Market Cap
$144.65M
Return on Assets (ROA)
-96.78%
TTM Avg
-33.63%
3Y Avg
-87.61%
5Y Avg
-84.15%
Market Cap
$145.54M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
Market Cap
$143.39M
Return on Assets (ROA)
-28.35%
TTM Avg
-69.97%
3Y Avg
-58.34%
5Y Avg
-49.63%
Market Cap
$146.71M
Return on Assets (ROA)
-76.12%
TTM Avg
-156.63%
3Y Avg
-142.29%
5Y Avg
-134.64%
Market Cap
$147.97M
Return on Assets (ROA)
-35.50%
TTM Avg
-18.07%
3Y Avg
-62.20%
5Y Avg
-134.72%
Market Cap
$140.10M
Return on Assets (ROA)
-59.36%
TTM Avg
-56.73%
3Y Avg
-42.41%
5Y Avg
-32.43%
Market Cap
$138.69M
Return on Assets (ROA)
-36.33%
TTM Avg
-27.39%
3Y Avg
-256.74%
5Y Avg
-207.88%
Market Cap
$138.62M
Return on Assets (ROA)
-6.07%
TTM Avg
-5.08%
3Y Avg
-4.92%
5Y Avg
-1.70%
Market Cap
$151.05M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | $144.65M | -96.78% | -33.63% | -87.61% | -84.15% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $145.54M | -90.55% | -70.80% | -45.07% | -40.08% |
| Immuneering Corporation (IMRX)vs › | $143.39M | -28.35% | -69.97% | -58.34% | -49.63% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $146.71M | -76.12% | -156.63% | -142.29% | -134.64% |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | -35.50% | -18.07% | -62.20% | -134.72% |
| Nyxoah S.A. (NYXH)vs › | $140.10M | -59.36% | -56.73% | -42.41% | -32.43% |
| Alpha Cognition Inc (ACOG)vs › | $138.69M | -36.33% | -27.39% | -256.74% | -207.88% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $138.62M | -6.07% | -5.08% | -4.92% | -1.70% |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.05M | -20.01% | -38.20% | -34.64% | -39.69% |
| Fortress Biotech, Inc. (FBIOP)vs › | $137.77M | 35.31% | -14.11% | -23.46% | -20.68% |
ROA
-96.8%
ROE
-131.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -35.33% |
| 2024-12-31 | -31.93% |
| 2023-12-31 | -39.35% |
| 2022-12-31 | -243.81% |
| 2021-12-31 | -87.05% |
| 2020-12-31 | -67.43% |
| 2019-12-31 | -65.96% |
| 2018-12-31 | -1557.25% |
| 2017-12-31 | -1717.04% |
| 2016-12-31 | 0.00% |
